brat1 Antibody

What epitopes should researchers target when selecting BRAT1 antibodies for functional studies?

BRAT1 antibodies are commonly raised against epitopes in either the C-terminal region or within the aa 750 to C-terminus of the protein. Research indicates that the C-terminal fragments of BRAT1 (#5 and #6) show strong binding to important interaction partners like ATM and DNA-PK . For functional studies examining BRAT1's role in DNA damage response, antibodies targeting the C-terminal region (such as EPR13753) are particularly effective as this region mediates critical protein-protein interactions .

When selecting antibodies, consider:

• Epitope location relative to functional domains

• Whether post-translational modifications might affect antibody recognition

• Cross-reactivity with related proteins

How should researchers validate BRAT1 antibody specificity in knockdown and overexpression models?

Proper validation is essential for BRAT1 antibody specificity. Based on methodologies described in recent publications, a comprehensive validation protocol should include:

• Western blot analysis comparing:

  • Control cells (shCtrl or empty vector)

  • BRAT1 knockdown cells (shBRAT1, showing approximately 10-25% residual expression)

  • BRAT1 overexpression cells (BRAT1-OE)

• Quantification methods:

  • Densitometric analysis of protein bands

  • qRT-PCR verification of mRNA levels (typically showing 60-75% reduction in KD models)

• Controls:

  • Loading controls such as actin

  • Multiple cell lines to ensure consistency (e.g., U251 GBM cells and NCH644 GSC lines)

For complete validation, researchers should observe a clear reduction in signal intensity in KD models and enhanced signal in OE models, with consistent results across multiple techniques.

What are the optimal sample preparation methods for BRAT1 detection in different subcellular compartments?

BRAT1 localizes to both nuclear and cytoplasmic compartments , requiring careful consideration of sample preparation methods:

For nuclear fraction analysis:

• Use nuclear extraction buffers containing DNase I to release chromatin-bound BRAT1

• Include phosphatase inhibitors to preserve phosphorylation status

• Avoid excessive sonication which may disrupt protein-protein interactions

For cytoplasmic fraction analysis:

• Use gentle lysis buffers (e.g., 0.5% NP-40 based)

• Include protease inhibitors to prevent degradation

• Centrifuge at lower speeds (1,000-3,000 × g) to avoid nuclear contamination

For whole-cell lysates:

• RIPA buffer with protease and phosphatase inhibitors

• Sonication may be necessary to release chromatin-bound BRAT1

Immunofluorescence studies should include co-staining with nuclear markers (DAPI) and cytoplasmic markers to accurately assess subcellular localization.

How should researchers optimize immunohistochemical detection of BRAT1 in glioblastoma tissue samples?

Based on recent glioblastoma research utilizing BRAT1 antibodies , optimized IHC protocols include:

• Tissue preparation:

  • Use formalin-fixed paraffin-embedded (FFPE) sections (4-6 μm thickness)

  • Antigen retrieval in citrate buffer (pH 6.0) for 20 minutes at 95°C

• Antibody application:

  • Dilution optimization: Start with 1/250 dilution as used in published studies

  • Incubation: Overnight at 4°C in humidified chamber

  • Detection system: DAB staining using anti-Rabbit IHC antibody at 1/100 dilution

• Controls:

  • Include normal brain tissue as negative/baseline control

  • Use known high BRAT1-expressing tumors as positive controls

  • Include isotype control antibodies to assess background

• Quantification approaches:

  • H-score (combining intensity and percentage of positive cells)

  • Digital image analysis for objective quantification

For challenging samples with high background, consider:

• Extended blocking steps (5% BSA or 10% normal serum)

• Lower antibody concentrations with extended incubation times

• Using tyramide signal amplification for weak signals

What methodological approaches can resolve contradictory results when studying BRAT1's role in DNA damage response?

Contradictory results in BRAT1 DNA damage research may stem from cell type-specific effects or experimental conditions. Based on published methodologies , researchers should implement:

• Standardized irradiation protocols:

  • Calibrate radiation doses based on cell type sensitivity

  • U251 cells: 10 Gy optimal dose

  • NCH644 GSCs: 8 Gy optimal dose

  • Consistent time points for analysis (1h and 24h post-irradiation)

• Comprehensive DNA damage markers:

  • γH2AX and 53BP1 foci quantification in parallel

  • Minimum of 100 cells counted per condition

  • Automated and manual counting for verification

• Genetic manipulation controls:

  • Include both knockdown and overexpression models

  • Use multiple shRNA constructs to rule out off-target effects

  • Rescue experiments to confirm specificity of observed phenotypes

• Cell line considerations:

  • Different cell types show different repair kinetics and BRAT1 dependencies

  • Account for p53 status, which affects DNA damage response pathways

  • Consider 2D vs. 3D culture systems for GSCs

When addressing contradictory results, a side-by-side comparison table documenting differences in experimental conditions can help identify variables contributing to discrepancies.

How can researchers effectively design experiments to study BRAT1's dual role in DNA repair and cell migration/invasion?

BRAT1 functions in both DNA repair and cell migration/invasion, requiring careful experimental design to dissect these roles. Based on recent methodologies :

• Sequential experimental approach:

  • First establish DNA repair phenotype using γH2AX/53BP1 foci assays

  • Then examine migration/invasion using appropriate assays for cell type:

    • Adherent GBM cells: IBIDI migration assay (2D wound healing)

    • GSCs: 3D transwell migration/Boyden chamber assays

• Temporal separation of phenotypes:

  • DNA repair phenotypes: Examine 1-24h post-irradiation

  • Migration/invasion: Examine 24-72h timeframes

  • Cell cycle analysis to account for proliferation effects

• Protein-specific domain analysis:

  • Use truncation mutants to separate DNA repair and migration functions

  • Implement point mutations in key functional domains

• Pharmacological approach:

  • Compare BRAT1 knockdown to Curcusone D (CurD) treatment

  • Use DNA repair inhibitors (ATM/DNA-PK inhibitors) vs. migration inhibitors

  • Combination approaches to test for synergistic effects

• In vivo validation:

  • Orthotopic mouse models to confirm both phenotypes in a physiological setting

  • Survival analysis (as shown with NCH644 shBRAT1 implantation leading to increased survival from 42.5 to 55 days)

What are the most effective approaches for studying BRAT1-protein interactions using immunoprecipitation?

Based on published methodologies , effective BRAT1 co-immunoprecipitation approaches include:

• Antibody selection for IP:

  • Use antibodies targeting C-terminal regions for optimal pulldown

  • Concentration: 1/30 dilution reported effective for BRAT1 IP

  • Consider both polyclonal and monoclonal antibodies for different applications

• Lysis conditions optimization:

  • For ATM/DNA-PK interactions: NP-40 based buffers with low salt (150mM NaCl)

  • For mTOR interactions: CHAPS-containing buffers to preserve mTORC1 integrity

  • Include both phosphatase and protease inhibitors

• Controls for specificity:

  • IgG control IP

  • BRAT1 knockdown cells as negative control

  • Reciprocal IP (pull down with suspected interactor antibody)

• Fragment-based approach:

  • Express GST-fusion fragments of BRAT1 (#3, 5, 6) and full-length (FL)

  • Use GSH-sepharose beads for immunoprecipitation (1 mg/sample)

  • Blot for suspected interaction partners (e.g., mTOR, Raptor, ATM)

• Verification of interactions:

  • Use multiple detection antibodies targeting different epitopes

  • Confirm with alternative methods (proximity ligation assay, FRET)

  • Map interaction domains using truncation mutants

Recent studies demonstrated that mTOR and Raptor bind to BRAT1, but Akt was not present in the BRAT1 complex, suggesting specificity for TORC1 rather than upstream components or TORC2 complex .

How should researchers design experiments to evaluate BRAT1 as a therapeutic target in glioblastoma?

Based on recent findings identifying BRAT1 as a potential therapeutic target for glioblastoma , researchers should implement a comprehensive experimental design:

• Expression analysis in patient samples:

  • Analyze BRAT1 expression across GBM datasets (e.g., TCGA, Gravendeel)

  • Correlate with patient survival (negative correlation observed)

  • Examine expression across tumor grades (increases with tumor grade)

• In vitro functional validation:

  • Generate stable BRAT1 knockdown models in multiple GBM cell lines and GSCs

  • Assess DNA repair capacity (γH2AX/53BP1 foci)

  • Evaluate migration/invasion (IBIDI/transwell assays)

  • Examine radiation sensitivity (clonogenic survival assays)

• Pharmacological targeting:

  • Test BRAT1 inhibitor Curcusone D (CurD) alone and in combination with radiation

  • Examine synergistic effects with standard-of-care temozolomide

  • Develop dose-response curves and determine IC50 values

• Ex vivo and in vivo validation:

  • Ex vivo slice culture models to assess tumor cell migration/invasion

  • Orthotopic mouse models to evaluate survival benefits

  • Assess toxicity profiles in normal tissues

• Biomarker development:

  • Identify downstream effectors of BRAT1 inhibition

  • Develop pharmacodynamic markers of response

  • Establish predictive biomarkers for patient selection

What methodological considerations are important when studying BRAT1 in neurological disorders?

BRAT1 is highly expressed in the brain and implicated in neurological disorders . When studying BRAT1 in this context, researchers should consider:

• Patient cohort characterization:

  • Comprehensive clinical phenotyping

  • Age-based stratification (median age at last follow-up reported as 20 months)

  • Consideration of consanguinity (39% of families in one cohort)

  • Ethnic diversity (patients from Latin America, North Africa, Sub-Saharan Africa, Middle East, East and Southeast Asia, and Caucasian descent)

• Genetic analysis approaches:

  • Whole exome/genome sequencing for variant identification

  • Functional validation of novel variants

  • Genotype-phenotype correlation analyses

• Tissue-specific considerations:

  • Brain region-specific BRAT1 expression analysis

  • Use of appropriate neuronal and glial cell models

  • Development of patient-derived iPSCs for disease modeling

• Developmental timing:

  • Embryonic vs. postnatal expression patterns

  • Temporal regulation during neuronal differentiation

  • Age-dependent phenotypes in model systems

• Functional readouts:

  • Neuronal morphology and connectivity

  • Electrophysiological parameters

  • Behavioral assessments in animal models

Recent studies identified 97 individuals from 74 unrelated families with BRAT1 biallelic variants , suggesting broader clinical relevance than previously recognized.

What experimental approaches should be used to investigate BRAT1's role in the mTOR signaling pathway?

BRAT1 is required for protein stability of mTOR and mTOR-related proteins . Based on published methodologies, researchers investigating this connection should:

• Protein stability analysis:

  • Compare mTOR protein levels in control vs. BRAT1 knockdown cells

  • Cycloheximide chase assays to measure protein half-life

  • Proteasome inhibition (MG132) to determine degradation mechanism

• mTOR activity assessment:

  • Monitor phosphorylation of downstream targets (p70S6K, 4E-BP1)

  • Examine response to serum starvation and restimulation

  • Compare rapamycin sensitivity in control vs. BRAT1-depleted cells

• Complex formation analysis:

  • Immunoprecipitation to examine mTORC1 vs. mTORC2 complex integrity

  • GST-pull down assays with BRAT1 fragments

  • Size exclusion chromatography to assess complex formation

• Nutrient and stress response:

  • Amino acid deprivation/readdition experiments

  • Glucose starvation

  • Hypoxia response

• Cell cycle regulation:

  • Synchronization experiments with serum starvation

  • Flow cytometry to quantify cell cycle phases

  • BrdU incorporation to measure DNA synthesis

Published data demonstrated that BRAT1 knockout MEFs showed alterations in cell cycle progression after serum starvation and restimulation, with significantly altered percentages of cells in sub-G1, G1, S, and G2/M phases .

What methodological approaches are most effective for studying BRAT1's role in neuronal differentiation?

Recent research has identified a role for BRAT1 in neuronal differentiation . To investigate this function:

• Neural differentiation models:

  • Human/mouse embryonic stem cells

  • Neural progenitor cells

  • Induced pluripotent stem cells (iPSCs)

  • Primary neuronal cultures

• BRAT1 manipulation strategies:

  • Inducible knockdown/knockout systems

  • Stage-specific manipulation (neural progenitor vs. differentiating neuron)

  • Rescue experiments with wild-type vs. mutant BRAT1

• ChIP-qPCR approaches:

  • Examine BRAT1 occupancy at specific gene promoters

  • Study relationship with Integrator complex components (INTS11)

  • Analyze chromatin accessibility changes (ATAC-seq)

• Differentiation markers:

  • Transcriptional profiling during differentiation stages

  • Immunofluorescence for neural markers

  • Morphological analysis of neurite outgrowth and branching

• Functional assessment:

  • Calcium imaging

  • Electrophysiological recording

  • Neurotransmitter release assays

Recent studies utilized ChIP-qPCR with specific antibodies to examine whether BRAT1 regulates the occupancy of INTS11 at the promoters of BRAT1-responsive genes , providing a methodological framework for further investigations.

How can researchers troubleshoot inconsistent BRAT1 detection in immunoblotting experiments?

When facing inconsistent BRAT1 detection in immunoblotting, researchers should systematically address:

• Sample preparation optimization:

  • Ensure complete lysis using appropriate buffers (RIPA for whole cell, NP-40 for nuclear)

  • Include protease inhibitors to prevent degradation

  • Avoid repeated freeze-thaw cycles of samples

• Protein transfer considerations:

  • BRAT1 is 88 kDa , requiring optimized transfer conditions

  • Use wet transfer for better efficiency with large proteins

  • Extended transfer times (overnight at lower voltage)

  • Methanol-free transfer buffer for larger proteins

• Blocking optimization:

  • Test different blocking agents (5% NFDM/TBST reported effective)

  • Optimize blocking time and temperature

  • Consider alternative blockers (BSA, commercial blockers) for high background

• Antibody selection and dilution:

  • Compare multiple antibodies targeting different epitopes

  • Optimize primary antibody dilution (1/30 reported effective for some applications)

  • Test different incubation conditions (overnight at 4°C vs. room temperature)

• Detection system considerations:

  • Enhanced chemiluminescence (ECL) vs. fluorescent detection

  • Exposure time optimization

  • Use of gradient gels for better separation

If inconsistency persists, consider comparing BRAT1 expression levels across different cell types, as expression may vary significantly between tissues.

What approaches can address non-specific binding in BRAT1 immunoprecipitation experiments?

Non-specific binding in BRAT1 IP experiments can be addressed through:

• Pre-clearing optimization:

  • Pre-clear lysates with protein A/G beads

  • Increase pre-clearing time (2-4 hours)

  • Use species-matched control IgG for pre-clearing

• Wash buffer stringency adjustment:

  • Increase salt concentration incrementally (150mM to 300mM NaCl)

  • Add low levels of detergent (0.1% NP-40/Triton X-100)

  • Increase number of washes (5-6 washes instead of standard 3-4)

• Antibody considerations:

  • Test monoclonal vs. polyclonal antibodies

  • Cross-link antibodies to beads to eliminate antibody contamination

  • Use recombinant antibody fragments (Fab) to reduce background

• Bead selection:

  • Compare magnetic vs. agarose beads

  • Test different bead capacities

  • Consider specialized low non-specific binding beads

• Elution optimization:

  • Native elution with peptide competition

  • Gradient elution to separate specific from non-specific binding

  • SDS elution only as a last resort to maintain complex integrity

In published BRAT1 IP experiments, researchers successfully used GSH-sepharose beads for pulldown of GST-fusion BRAT1 fragments at 1 mg/sample concentration .

What emerging technologies will advance our understanding of BRAT1's diverse cellular functions?

Future BRAT1 research will benefit from integrating these advanced technologies:

• Proximity labeling approaches:

  • BioID or TurboID fusion with BRAT1 to identify proximal proteins

  • APEX2-based proximity labeling for subcellular compartment-specific interactors

  • Compartment-specific interactome mapping (nuclear vs. cytoplasmic BRAT1)

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize BRAT1 at DNA damage sites

  • Live-cell imaging with fluorescently tagged BRAT1

  • FRET-based sensors to detect BRAT1 conformational changes

• Single-cell analysis:

  • scRNA-seq to identify cell type-specific responses to BRAT1 modulation

  • CyTOF analysis for protein-level changes in heterogeneous populations

  • Spatial transcriptomics in tumor samples

• CRISPR-based approaches:

  • CRISPR activation/inhibition for temporal control of BRAT1 expression

  • CRISPR base editing for modeling patient mutations

  • CRISPR screens to identify synthetic lethal interactions

• Structural biology:

  • Cryo-EM of BRAT1-containing complexes

  • Hydrogen-deuterium exchange mass spectrometry for dynamic structural changes

  • AlphaFold-based predictions to guide functional studies

Integrating these approaches will help resolve the multifaceted functions of BRAT1 in DNA damage response, cell migration, and mTOR signaling.

How can researchers develop improved tools for studying BRAT1 in complex tissue environments?

Development of advanced tools for BRAT1 study in complex tissues should include:

• Tissue-specific antibody validation:

  • Validation in multiple tissue types with variable BRAT1 expression

  • Optimization for multiplex immunofluorescence

  • Comparison across FFPE, frozen, and fresh tissue preparations

• Reporter systems:

  • BRAT1 promoter-driven fluorescent reporters for live imaging

  • Knock-in fluorescent tags at endogenous loci

  • Activity-based sensors for BRAT1 function

• Spatial biology approaches:

  • Optimization of RNAscope protocols for BRAT1 mRNA detection

  • Digital spatial profiling to correlate BRAT1 with tissue microenvironments

  • Multiplexed ion beam imaging for subcellular localization

• Tissue clearing techniques:

  • CLARITY/iDISCO-compatible BRAT1 antibodies

  • Whole-organ imaging of BRAT1 expression patterns

  • 3D reconstruction of BRAT1 distribution in intact tissues

• In situ protein interaction detection:

  • Proximity ligation assays for visualizing BRAT1 interactions in tissue

  • CODEX multiplexed protein detection

  • Spatial proteomics approaches

These advanced tools will facilitate understanding BRAT1's roles in development, disease progression, and treatment response in physiologically relevant contexts.